Duliege Anne-Marie 4
4 · RIGEL PHARMACEUTICALS INC · Filed Sep 6, 2018
Insider Transaction Report
Form 4
Duliege Anne-Marie
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2018-09-04$2.54/sh+16,500$41,910→ 16,500 total - Exercise/Conversion
Employe Stock Option (right to buy)
2018-09-04−16,500→ 383,500 totalExercise: $2.54Exp: 2026-05-05→ Common Stock (16,500 underlying) - Sale
Common Stock
2018-09-04$3.51/sh−16,500$57,861→ 0 total
Footnotes (3)
- [F1]The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 26, 2018.
- [F2]The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions ranging from $3.50 to $3.53. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the shares sold at each such separate price.
- [F3]One fourth (1/4th) of the option vests one (1) year from March 7, 2016 and thereafter the balance of the option vests in equal monthly installments over the next thirty-six (36) months.